7JN Stock Overview
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom.
Notes are coming soon
Poolbeg Pharma PLC Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||UK£0.09|
|52 Week High||UK£0.11|
|52 Week Low||UK£0.037|
|1 Month Change||55.17%|
|3 Month Change||36.36%|
|1 Year Change||4.65%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-3.02%|
Recent News & Updates
|7JN||DE Pharmaceuticals||DE Market|
Return vs Industry: 7JN exceeded the German Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: 7JN exceeded the German Market which returned -11.6% over the past year.
|7JN Average Weekly Movement||18.3%|
|Pharmaceuticals Industry Average Movement||5.8%|
|Market Average Movement||5.2%|
|10% most volatile stocks in DE Market||10.2%|
|10% least volatile stocks in DE Market||2.4%|
Stable Share Price: 7JN is more volatile than 90% of German stocks over the past 3 months, typically moving +/- 18% a week.
Volatility Over Time: 7JN's weekly volatility (18%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Poolbeg Pharma plc operates as a clinical stage infectious disease pharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass intranasally administered RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. The company also has a licensed access to micro and nanoencapsulation technology to develop an oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut; and artificial intelligence powered drug program.
Poolbeg Pharma PLC Fundamentals Summary
|7JN fundamental statistics|
Is 7JN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|7JN income statement (TTM)|
|Cost of Revenue||UK£0|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0062|
|Net Profit Margin||0.00%|
How did 7JN perform over the long term?See historical performance and comparison